Ukrainian Medicines Without Borders: In Six Months, Darnytsia Submitted 10 Medicines for Registration in 7 Countries Worldwide

In the first half of 2025, Darnytsia Pharmaceutical Company made a significant step towards international recognition—within just six months, 10 modern medicinal products were submitted for registration in 7 countries around the world.

The geography of the new applications covers countries such as Saudi Arabia, Vietnam, Uzbekistan, the United Kingdom, Bosnia and Herzegovina, New Zealand, and Australia.

The products submitted by Darnytsia represent key therapeutic areas, including cardiology, nephrology, infectious diseases, and intensive care. Among them are medicines for the treatment of cardiovascular diseases, arterial hypertension, heart failure, as well as products for combating infections and supporting the body during critical conditions. These are vital solutions for patients with chronic and acute illnesses, helping to preserve health and quality of life.

“Entering new markets is not just a strategic step for Darnytsia, but also our responsibility to patients around the world. We strive to ensure that high-quality Ukrainian medicines are available in different corners of the planet. Our international ambitions are a belief in our own strength, in our team, and in a future where health knows no borders,” says Anna Pavliuk-Havrylova, Head of the Department of International Registration and Market Expansion at Darnytsia Pharmaceutical Company.

Darnytsia is confidently expanding its presence in the global pharmaceutical market, proving that Ukrainian products are competitive on the world stage. The company plans to further expand its portfolio and geographic reach so that even more patients can access modern and effective medicines.

For reference, in 2024, Darnytsia obtained registration for 10 medicinal products outside Ukraine and entered 6 new markets, including EU countries, Bosnia and Herzegovina, Israel, New Zealand, and Malaysia.